# Akebia Therapeutics, Inc. (AKBA) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Akebia Therapeutics, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/AKBA/mda/fy2025/): filed 2026-02-26; accession 0001517022-26-000020 (https://www.sec.gov/Archives/edgar/data/1517022/000151702226000020/akba-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/AKBA/mda/fy2024/): filed 2025-03-13; accession 0001628280-25-012470 (https://www.sec.gov/Archives/edgar/data/1517022/000162828025012470/akba-20241231.htm)
- [FY 2023 MD&A](/company/AKBA/mda/fy2023/): filed 2024-03-14; accession 0001628280-24-011270 (https://www.sec.gov/Archives/edgar/data/1517022/000162828024011270/akba-20231231.htm)
- [FY 2022 MD&A](/company/AKBA/mda/fy2022/): filed 2023-03-10; accession 0001628280-23-007539 (https://www.sec.gov/Archives/edgar/data/1517022/000162828023007539/akba-20221231.htm)
- [FY 2021 MD&A](/company/AKBA/mda/fy2021/): filed 2022-03-01; accession 0001628280-22-004522 (https://www.sec.gov/Archives/edgar/data/1517022/000162828022004522/akba-20211231.htm)

Back to /company/AKBA/